BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Society of Cannabis Clinicians - ECPv6.15.15//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Society of Cannabis Clinicians
X-ORIGINAL-URL:https://www.cannabisclinicians.org
X-WR-CALDESC:Events for Society of Cannabis Clinicians
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220304T090000
DTEND;TZID=America/Los_Angeles:20220304T090000
DTSTAMP:20260608T100848
CREATED:20220208T221302Z
LAST-MODIFIED:20220301T211456Z
UID:10000100-1646384400-1646384400@www.cannabisclinicians.org
SUMMARY:Monthly Journal Club: Bonni Goldstein\, MD & Itzhak Kurek\, PhD - Cannabis-Responsive Biomarkers & Autism Spectrum Disorder
DESCRIPTION:March 4\, 2022 at 9am PST / 12pm EST\n\nArticle: Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.\n\nSpeakers: Bonni Goldstein\, MD & Itzhak Kurek\, PhD \nModerator: Zach Moore\, PhD\n\nEvent registration link: https://cannabisclinicians.tradewing.com/event/Q5HfwtB9iCxhaMCed\nJoin us for a robust discussion with Bonni Goldstein\, MD & Itzhak Kurek\, PhD moderated by Zach Moore\, PhD as we discover their newest publication\, “Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.” \nAutism spectrum disorder (ASD) is a group of neurodevelopmental conditions that impact behavior\, communication\, social interaction\, and learning abilities. Treatment of ASD with medical cannabis (MC) shows promising results in reducing the severity of certain behavioral aspects. The goals of this observational study are to demonstrate the potential of metabolic biomarkers to (1) objectively determine the impact on metabolites of MC treatment and (2) suggest the metabolic pathways of children with ASD\, who respond to MC treatment. \n\nLearn More About Dr. Bonni Goldstein: \nDr. Bonni Goldstein \nBonni Goldstein\, MD is the Medical Director of Canna-Centers Wellness & Education\, a California-based medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions.  She completed her internship and residency at Children’s Hospital Los Angeles\, where she also served as chief resident.  After years of working in the specialty of Pediatric Emergency medicine\, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.  Over the last 13 years she has evaluated thousands of patients for use of medical cannabis and is recognized as an expert in the clinical application of cannabis therapeutics.  She has a special interest in treating children with intractable epilepsy\, autism\, cancer and other conditions. Her latest book\, “Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain” was published in September 2020 by Little\, Brown Spark. Dr. Goldstein recently co-authored a peer-reviewed article researching the use of Cannabis-Responsive biomarkers to document cannabis treatment efficacy\, guide clinical decision-making and improve outcomes. \n\nLearn More About Itzhak Kurek\, PhD: \nItzhak Kurek\, PhD \nItzhak Kurek\, PhD is the co-founder and CEO of Cannformatics\, Inc. a San Francisco-based biotechnology startup developing saliva-based Cannabis-Responsive™ biomarkers as a universal tool for the objective measurement of the physiological impact of any cannabinoid-based treatment. He has executive and research management experience in the Ag-Biotech\, Nutritional Supplements and Biobased Products businesses. Previously he held positions at Solix Algredients\, Kiverdi\, Pioneer Hi-Bred (DuPont) and Maxygen. He has published over 70 peer-reviewed scientific papers and patents. Dr. Kurek received his Ph.D. in Plant Sciences from Tel Aviv University and completed his postdoctoral research at the University of California\, Davis. Dr. Kurek has also conducted research at the Technical University of Munich\, John Innes Center Norwich\, C.N.R.S Bordeaux and the Lawrence Berkeley National Laboratories. \n  \nREGISTER TO ATTEND
URL:https://www.cannabisclinicians.org/event/monthly-journal-club-bonni-goldstein-md-itzhak-kurek-phd-cannabis-responsive-biomarkers-autism-spectrum-disorder/
ATTACH;FMTTYPE=image/jpeg:https://www.cannabisclinicians.org/wp-content/uploads/2022/02/CannaTalk-with-Dr.-Goldstein-Kurek-IGFB.jpg
ORGANIZER;CN="Society of Cannabis Clinicians":MAILTO:info@cannabisclinicians.org
END:VEVENT
END:VCALENDAR